Expert Consensus on Clinical Application of Ruyi Zhenbaowan
10.13422/j.cnki.syfjx.20251494
- VernacularTitle:如意珍宝丸临床应用专家共识
- Author:
Ming CHEN
1
;
Jingling CHANG
2
;
Shangquan WANG
3
;
Gejia ZHONG
4
;
Qiang DENG
5
;
Hongxia CHEN
6
;
Qien LI
7
;
Yaming LIN
8
;
Zujian XU
9
;
Changkuan FU
1
;
Yuer HU
1
;
Yanming XIE
1
;
Yuanyuan LI
1
Author Information
1. Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China
3. Wangjing Hospital of China Academy of Chinese Medical Sciences，Beijing 100102，China
4. Beijing Hospital of Tibetan Medicine， China Tibetology Research Center，Beijing 100029，China
5. Gansu Provincial Hospital of TCM，Lanzhou 730050，China
6. Guangdong Provincial Hospital of TCM， Guangzhou 510120，China
7. Tibetan Medical College， Qinghai University，Xining 810016，China
8. Yunnan Provincial Hospital of TCM，Kunming 650021，China
9. The Affiliated TCM Hospital of Southwest Medical University，Luzhou 646000，China
- Publication Type:Journal Article
- Keywords:
Ruyi Zhenbaowan;
expert consensus;
osteoarthritis;
stroke;
Tibetan medicine
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(16):173-183
- CountryChina
- Language:Chinese
-
Abstract:
Osteoarthritis （OA） and stroke are common clinical diseases that reduce patients' quality of life and place a burden on families and society. Ruyi Zhenbaowan， a classic prescription in Tibetan medicine， have the functions of clearing heat， awakening the brain and opening orifices， relaxing tendons and promoting meridian circulation， and eliminating yellow water. Clinically， they are used to treat osteoarthritis， post-stroke sequelae， neuropathic pain， and other related conditions. Modern pharmacological studies have demonstrated their anti-inflammatory， analgesic， and nerve-repairing effects. However， current research remains insufficient regarding the appropriate indications， timing， and efficacy of this medicine in treating relevant diseases. To enhance clinicians' understanding of this medicine and promote its standardized and rational clinical use， a panel of national experts， including clinical specialists， Tibetan medicine practitioners， pharmacologists， and methodologists， formulated this consensus based on clinical experience and evidence-based practice. The Cochrane systematic review framework， the Grading of Recommendations Assessment， Development and Evaluation （GRADE） system， and the nominal group method were employed to generate seven graded recommendations and 19 consensus-based suggestions. These recommendations clearly define the key points in the clinical application of Ruyi Zhenbaowan， including therapeutic indications， dosage and administration， treatment duration， and medication safety. The consensus specifically addresses the clinical efficacy， appropriate timing of administration， dosage strategies， treatment cycles， and combination medication strategies for treating osteoarthritis and stroke and provides an overview of safety considerations. The aim is to provide standardized guidance for hospitals and healthcare institutions nationwide to ensure the rational application of Ruyi Zhenbaowan in the treatment of osteoarthritis and stroke， reduce medication-related risks， and further leverage its clinical advantages. This consensus has been approved and issued by the China Association of Chinese Medicine， with the standard number GS/CACM 369-2024.
